Dynavax Technologies Corp. (NASDAQ:DVAX) issued its quarterly earnings data on Monday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01, StockRatingsNetwork reports. Dynavax Technologies Corporation (NASDAQ:DVAX) weekly performance is -18.24%. On last trading day company shares ended up $1.30. Analysts mean target price for the company is $4.50. Dynavax Technologies Corporation (NASDAQ:DVAX) distance from 50-day simple moving average (SMA50) is -23.92%.
On May 1, 2014, Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued a press release announcing its financial results for the first quarter of 2014. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares fell -12.33% in last trading session and ended the day on $11.09. CLDX return on assets is -34.40%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) quarterly performance is -52.46%.
Insulet Corp. (NASDAQ:PODD) was down during trading on Thursday after the company announced weaker than expected quarterly earnings, StockRatingsNetwork. Insulet Corporation (NASDAQ:PODD) shares moved down -10.45% in last trading session and was closed at $31.69, while trading in range of $31.69 – $35.00. Insulet Corporation (NASDAQ:PODD) year to date (YTD) performance is -14.58%.
OraSure Technologies, Inc. (NASDAQ:OSUR) Consolidated net revenues for the first quarter of 2014 were $23.5 million, an 11% increase from the comparable quarter of 2013. Net product revenues increased 12% primarily due to higher revenues from the Company’s molecular collection systems subsidiary, DNA Genotek (“DNAG”), and higher sales of the Company’s OraQuick(R) HCV test, cryosurgical systems products, and OraQuick(R) In-Home HIV test. OraSure Technologies, Inc. (NASDAQ:OSUR) ended the last trading day at $6.03. Company weekly volatility is calculated as 6.21% and price to cash ratio as 3.66.OraSure Technologies, Inc. (NASDAQ:OSUR) showed a negative weekly performance of -6.94%.
Leave a Reply